Inhibitors of histone deacetylase and MCL-1 synergistically reduce proliferation in malignant melanoma

Mehrnoosh Ghafouri  
*Wayne State University School of Medicine*, mehrnoosh.ghafouri@med.wayne.edu

Chester Gauss  
*Western Michigan University School of Medicine*

Yue Xi PhD  
*Wayne State University School of Medicine*

William Azkoul II MD  
*Wayne State University School of Medicine*

Abby Knudsen  
*Wayne State University School of Medicine*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wayne.edu/som_srs](https://digitalcommons.wayne.edu/som_srs)

Part of the Dermatology Commons, Otolaryngology Commons, and the Pediatrics Commons

**Recommended Citation**

Ghafouri, Mehrnoosh; Gauss, Chester; Xi, Yue PhD; Azkoul, William II MD; Knudsen, Abby; Zuckerman, Jordan; Michelhaugh, Sharon K. PhD; Mittal, Sandeep MD; and Fribley, Andrew M. PhD, "Inhibitors of histone deacetylase and MCL-1 synergistically reduce proliferation in malignant melanoma" (2023).  
*Medical Student Research Symposium*. 258.  
[https://digitalcommons.wayne.edu/som_srs/258](https://digitalcommons.wayne.edu/som_srs/258)

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Inhibitors of histone deacetylase and MCL-1 synergistically reduce proliferation in malignant melanoma

Keywords: Melanoma, histone deacetylase inhibitors, panobinostat, MCL-1 inhibitor, AZD5991, apoptosis, GADD

Melanoma is a skin cancer that arises in melanocytes; it is the fifth most common cancer in the United States with approximately 100,000 new cases per year. Current treatments for malignant melanoma are surgical excision, radiation therapy and systemic therapy; however, the five-year survival rate for patients with stage IV is 29.8%. There is an urgent unmet clinical need to investigate novel treatments for these patients. Panobinostat is an orally available histone deacetylase inhibitor used in several hematologic malignancies, but it was ineffective as a single agent against melanoma in Phase 1. To address the insufficiency of options for melanoma patients, we treated a panel of cultured melanoma cell lines with panobinostat and the novel preclinical MCL-1 inhibitor AZD5991. We hypothesized the addition of AZD5991 (currently in phase 3) would enhance the antiproliferative effect of panobinostat in vitro. MTT and ATP-based proliferation assays demonstrated a significant reduction in proliferation when treated with either panobinostat or AZD5991. Isobologram analysis revealed that much lower concentrations of each drug was required to increase caspase 3/7 activity, induce a panel of Growth and DNA Damage (GADD) gene transcripts, and reduce proliferation when the drugs were added in combination. These in vitro studies revealed that panobinostat and AZD5991 synergistically inhibit melanoma growth. Increased caspase activation and the accumulation of GADD transcripts suggests apoptosis is a key feature of the antiproliferative mechanism. Ongoing studies are focused to further characterize panobinostat/AZD5991- induced cell death and to validate our cell culture observations in patient-derived xenograft models.